MARC details
000 -LIDER |
fixed length control field |
05098nam a22005175i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-319-40136-2 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20180206183020.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
161013s2016 gw | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783319401362 |
-- |
978-3-319-40136-2 |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
QR180-189.5 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJCM |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED044000 |
Source |
bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
616.079 |
Edition number |
23 |
245 10 - TITLE STATEMENT |
Title |
Systemic Vasculitides: Current Status and Perspectives |
Medium |
[recurso electrónico] / |
Statement of responsibility, etc. |
edited by Franco Dammacco, Domenico Ribatti, Angelo Vacca. |
264 #1 - |
-- |
Cham : |
-- |
Springer International Publishing : |
-- |
Imprint: Springer, |
-- |
2016. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
XI, 438 p. 78 illus., 55 illus. in color. |
Other physical details |
online resource. |
336 ## - |
-- |
text |
-- |
txt |
-- |
rdacontent |
337 ## - |
-- |
computer |
-- |
c |
-- |
rdamedia |
338 ## - |
-- |
online resource |
-- |
cr |
-- |
rdacarrier |
347 ## - |
-- |
text file |
-- |
PDF |
-- |
rda |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Preface -- Introductory remarks -- Giant Cell Arteritis -- Takayasu Arteritis -- Polyarteritis Nodosa -- Mechanisms of ANCA-Associated Vasculitides -- Granulomatosis with Polyangiitis (Wegener´s) and Similar ?AAV with Probable Etiology? -- Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss) -- Anti-Glomerular Basement Membrane Disease -- IgA Vasculitis -- HCV-Related Cryoglobulinemic Vasculitis -- Vasculitis and Pulmonary Hypertension: New Therapeutic Approaches -- Vasculitis in SLE, RA and Other Connective Tissue Diseases: Diagnosis and Treatment -- Central Nervous System Vasculitis -- Uveitis -- IgG4 Syndrome -- Behçet Syndrome -- Urticarioid Vasculitis -- Guidelines for the Diagnosis and Treatment of Vasculitides -- Index. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
The systemic vasculitides,includinglarge, medium, small, and variable vessel vasculitis,have been the focus of intensive basic and clinical investigations over the last twodecades. Among theimportant advances stemming from these efforts are new definitions, classifications, and diagnostic criteria for the different classes of vasculitis; the addition of anti-neutrophil cytoplasmic autoantibodies as a new criterion for classifying vasculitis; the recognition of the viral etiology of conditions such as cryoglobulinemic vasculitis and polyarteritis nodosa; an appreciation of thebroad spectrum of clinical manifestations and potentially devastating complicationsassociated with vasculitis; the many features and remarkable clinical heterogeneity of IgG4-related, immune-mediated diseases; and the proposal of intriguing pathogenetic hypotheses for certain chronic, relapsing vasculitides. This improved understanding of the systemic vasculitides has been accompanied by a trend away from the use of eponyms for these conditions; thus, established terms such as Wegener´s granulomatosis and Churg-Strauss syndrome have been replacedby the more descriptive definitions ?granulomatosis with polyangiitis? and ?eosinophilic granulomatosis with polyangiitis,? respectively. Additional clinical laboratory tests,rapidly developing imaging techniques that can assess inflammation, especially in large-vessel vasculitis, and artificial neural network approaches will no doubt bring a wealth of informationthat ultimately leads to the identification of novel disease biomarkers. Expected applications include the identification of individuals at increased risk ofrelapsewho would benefit from patient-tailored therapy. Although the conventional combination of glucocorticoids and immunosuppressive drugs is effective in the treatment of a large proportion of vasculitic disorders, safer medications, with fewer side effects, are being developed, includingseveral biological agents now being closely evaluated in multi-center studies. This volume brings togethercomprehensive and up-to-date reviews written by experiencedscientists and clinicians from many countries. Its aim is toprovide readers with state-of-the-art knowledge of the major vasculitides and cutting-edge insights into their multi-faceted features. It is our hope that this book serves as a valuable and stimulating resourcefor basic and clinical researchers, specialists in related disciplines, as well as practicing physicians and advanced medical students interested in this fascinating branch of pathology. Franco Dammacco, Domenico Ribatti, Angelo Vacca. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Medicine. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Immunology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Neurosciences. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Pharmacology. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Virology. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Biomedicine. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Immunology. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Neurosciences. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Pharmacology/Toxicology. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Término temático o nombre geográfico como elemento de entrada |
Virology. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Dammacco, Franco. |
Relator term |
editor. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Ribatti, Domenico. |
Relator term |
editor. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Vacca, Angelo. |
Relator term |
editor. |
710 2# - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY |
Title |
Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9783319401348 |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Public note |
Libro electrónico |
Uniform Resource Identifier |
http://148.231.10.114:2048/login?url=http://dx.doi.org/10.1007/978-3-319-40136-2 |
912 ## - |
-- |
ZDB-2-SBL |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Libro Electrónico |